- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Federal Negotiations for Medicare Part D Drug Pricing?
The President's budget proposal for 2016 seeks to gain the ability to negotiate drug prices under Medicare Part D, which will definitely face resistance from the Republican-controlled Congress.
The Obama administration said on Monday it would seek authority to negotiate pricing for high-cost drugs under the federal government's Medicare Part D program, which offers private insurance drug coverage for senior citizens and the disabled.
Barack Obama's new $3.99 trillion budget for fiscal-year 2016 proposes allowing the US Secretary for HHS to negotiate prices for biotechnology treatments and other high-cost drugs in Part D "to ensure access to and affordability of these treatments."
The move to add negotiating authority on drug prices is likely to draw fierce resistance in the Republican-controlled Congress. Lawmakers prohibited Medicare from negotiating prices directly with drug companies when it created the voluntary Part D program under former President George W. Bush in 2003.
Link to the complete Reuters article: http://reut.rs/1yw1pgs
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Care Quality Metrics in Medicare During COVID-19 Pandemic
August 12th 2025Medicare Advantage outperformed traditional Medicare on clinical quality measures before and during the COVID-19 pandemic; mid-pandemic, however, traditional Medicare narrowed the gap on some in-person screenings.
Read More
